Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 9, Number 10—October 2003


Severe Histoplasmosis in Travelers to Nicaragua

Michelle Weinberg*Comments to Author , Julia Weeks†, Susan Lance-Parker‡, Marc Traeger*§, Steven Wiersma§, Quyen N. Phan¶, David Dennison#, Pia MacDonald***, Mark Lindsley*, Jeannette Guarner*, Patricia Connolly††, Martin S. Cetron*, and Rana Hajjeh*
Author affiliations: *Centers for Disease Control and Prevention, Atlanta, Georgia, USA; †Archbold Urgent Care Center, Thomasville, Georgia, USA; ‡Georgia Department of Human Resources, Division of Public Health, Atlanta, Georgia, USA; §Florida Department of Health, Tallahassee, Florida, USA; ¶Connecticut Department of Public Health, Hartford, Connecticut, USA; #Highlands-Cashiers Hospital, Highlands, North Carolina, USA; **North Carolina Division of Public Health, Raleigh, North Carolina, USA; ††Indiana University School of Medicine and Histoplasmosis Reference Laboratory, Indianapolis, Indiana, USA

Main Article


Summary of laboratory testing results and clinical outcomes among persons with histoplasmosis

Characteristic N (%)
Diagnostic test resulta

CFb and IDc positive
5 (36)
CF positive, ID negative
8 (57)
ID positive, CF negative
1 (7)
Urine antigen positived
7 (58), range 1.2–4.6, median 2.8
Clinical outcomese

Missed work, school, or bothf
10 (83)
Treated with itraconazole
9 (75)
Treated with steroids
7 (58)
6 (50)
Duration of hospitalization
Median 6 d (range 2–11 d)
Duration of fever
Median 12 d (range 4–26 d)
Duration of symptoms Median 42 d (range 16–210 d)

aAmong 14 persons with histoplasmosis.
bCF: complement fixation.
cID: immunodiffusion.
dUrine antigen tests were performed for 12 persons.
eAmong the 12 symptomatic persons.
fFive persons missed 2 weeks–3 months of work, and five persons missed one semester of school.

Main Article